Prospective Observational Cohort HIV & STI Study in Europe
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03866759|
Recruitment Status : Not yet recruiting
First Posted : March 7, 2019
Last Update Posted : April 17, 2019
The University Hospital Essen is sponsoring the Multicenter human immunodeficiency virus (HIV) and sexually transmitted infections Prevention Network Study (STIPnet) which is funded by Janssen, Pharmaceutical Companies of Johnson & Johnson.
STIPnet study is a prospective observational cohort study aiming to determine the incidence and point prevalence of HIV infection and the most common sexually transmitted infections (STIs) in individuals with sexual risk behavior. In addition, the University Hospital Essen will examine whether individuals at risk for HIV and STI infections would retain in such a study (retention rate) and would be willing to participate in potential HIV and STI prevention trials (willingness to participate).
|Condition or disease||Intervention/treatment|
|HIV Infections HIV-1-infection Risk Reduction Sexual Behavior||Behavioral: Determine the Incidence and Point Prevalence|
To develop and test novel prevention methods or interventions against sexually transmitted infections (STIs), knowledge is required on whether there are increased rates of transmission in a given population. In order for trials testing new prevention methods to be feasible and affordable, the goal is to define a group at risk where there will be at least an annual 3% incidence of new infections of the respective STI. The group definitions will be based on factors such as gender, age, sexual behavior, economic status and others. However, defining such groups is labor-intensive and costly and often not do-able for vaccine developers and developers of novel prevention/diagnostic methods. Thus, as identification and testing of the most at-risk groups to study these medicinal products is too costly, only a limited number of novel prevention methods are brought into clinical trials. Here the investigators plan to define factors such as behavioral or co-infections associated with individual STIs for potential future prevention trials. Given the increased susceptibility of human immunodeficiency (HIV) infection with STI infections, early diagnosis and treatment of STI is substantial to reduce risk factor of HIV acquisition and to inform individuals about their risk of becoming HIV infected. As STIs are a crucial factor in the scope of an incidence analysis of HIV in men who have sex with men (MSM) and are often underdiagnosed, extensive screening measures are implemented within this study.
Thus, the STIPnet study is building up a platform for effective recruitment, retention and assess important epidemiological patterns and thus, designed as a vaccine preparedness study, to gather information on the most common STIs and prepare sites for potential future vaccine trials. Indeed, several potential HIV&STI vaccines are currently in development.
At-risk volunteers are screened every three months for HIV and other STIs, thereby establishing disease prevalence and incidence in communities that might someday support future vaccine trials. Behavioural data are also collected and participants complete a questionnaire that assesses the willingness to participate in future vaccine studies.
|Study Type :||Observational|
|Estimated Enrollment :||4500 participants|
|Official Title:||European HIV&STI Prevention Network Study|
|Estimated Study Start Date :||May 2019|
|Estimated Primary Completion Date :||March 2021|
|Estimated Study Completion Date :||March 2024|
- Behavioral: Determine the Incidence and Point Prevalence
Determine the Incidence and Point Prevalence of human immunodeficiency virus (HIV) Infection and the Most Common Sexually Transmitted Infections in Individuals With Sexual Risk Behavior.
- Choice of a cohort of volunteers at-risk for HIV and other STIs [ Time Frame: Through study completion, an average of 2 years ]Participants will receive questionnaires. The group definitions will be based on factors such as gender, age, education, sexual behavior, economic status, pre- and post-exposure prophylaxis and others. Descriptive statistics will be generate to choose a cohort of volunteers at-risk for HIV and other STIs.
- Relationship between STIs and certain behavior and risk of HIV infection [ Time Frame: Through study completion, an average of 2 years ]Participants will receive a questionnaire about behavior and risk of HIV infection. Descriptive statistics will be generate to summarize the relationship between STIs and HIV infection.
- Incidence of HIV and other STIs in a cohort of individuals at risk for HIV and other STI infections [ Time Frame: Through study completion, an average of 2 years ]Descriptive statistics will be generated to summarize incidence (as measured as new HIV and STI infections occurring during the study period) HIV and STI infections. The power calculation targets a 3% incidence rate per year.
- Prevalence of HIV and other STIs in a cohort of individuals at risk for HIV and other STI infections [ Time Frame: At screening (until last participant is included), an average of 1 year ]
Descriptive statistics will be generated to summarize prevalence (as measured as HIV and STIs positive cases during screening visit) HIV and STI infections. Baseline HIV and STI prevalence will be defined as the number of HIV or STI infected individuals identified at screening divided by the total number of individuals who are screened for HIV or STI.
Once enrollment is completed, baseline HIV or STI prevalence will be calculated.
- Co-occurence of STIs and HIV [ Time Frame: Through study completion, an average of 2 years ]Analysis of laboratory and other testing results. Descriptive statistics will be generated to evaluate co-occurence of STIs and HIV.
- Retention rates for prospective prevention studies for individuals at risk for HIV and STI infections. [ Time Frame: Through study completion, an average of 2 years ]The primary assessment of retention will be conducted assuming a binomial distribution and individuals will be considered retained at 12 months if they complete the final study visit. Retention will also be estimated with 95% CI for each study visit. A summary of participant attendance and loss to follow-up will be made every 3 months to monitor the retention rate by site, and to help ensure that the overall 12-month retention rate of the study visit will be no less than 85%.
- Willingness to participate in future clinical trials, such as those of candidate vaccines through questionnaire [ Time Frame: At enrollment (day 0, can be same day as screening day) and at visit 4 (visit 4 is day 364) ]Willingness to participate in vaccine trials will be estimated assuming a binomial distribution. Factors associated with willingness to participate in vaccine trial will be evaluated using logistic regression models
- Attitudes regarding HIV and STI prevention methods [ Time Frame: At screening, at visit 1, 2, 3, 4 (visit 1 is day 84, visit 2 is day 168, visit 3 is day 252 and visit 4 is day 364) ]Attitudes regarding PrEP will be evaluated using descriptive statistics and questionnaires. Behavioral questionnaire over time will be assessed by frequency tables and bar graphs.
- Incidence between individuals at risk for HIV and STI infections across sites and countries [ Time Frame: Through study completion, an average of 2 years ]Descriptive statistics will be generated to summarize incidence (as measured as new HIV and sexual transmitted infections occurring during the study period) HIV and STI infections. Data may be compared across sites for comparison and evaluation of factors impacting incidence.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03866759
|Contact: Hendrik Streeck, Prof. Dr.||+49 (0)201 / firstname.lastname@example.org|
|Contact: Anna-Lena Brillen, Dr.||+49 (0)201 / email@example.com|
|Principal Investigator:||Hendrik Streeck, Prof. Dr.||Institute for HIV Research|